Polymerase

Enable Medicine Appoints Kamni Vijay as Chief Executive Officer

Retrieved on: 
Tuesday, February 13, 2024

Enable Medicine , a leader in AI for biological research and drug discovery, has announced the appointment of Kamni Vijay as Chief Executive Officer.

Key Points: 
  • Enable Medicine , a leader in AI for biological research and drug discovery, has announced the appointment of Kamni Vijay as Chief Executive Officer.
  • Mr. Bodapati remains Chairman of the Board and will transition to the role of Chief Strategy Officer.
  • “Kamni Vijay is highly respected in the life sciences and diagnostics industries,” said Elena Viboch, Partner at General Catalyst.
  • “Kamni brings to Enable extensive experience leading high-performing teams and is exactly the type of leader Enable needs as we advance into our next phase of growth,” said Sunil Bodapati, Chairman and Co-Founder, Enable Medicine.

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

EQS-News: Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

Retrieved on: 
Tuesday, August 1, 2023

Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics.

Key Points: 
  • Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics.
  • Colorectal cancer remains a critical health concern, with approximately 43,000 diagnoses and 16,800 deaths occurring each year in the UK alone.
  • Mainz Biomed is delighted to collaborate with Marylebone Laboratory, which recently expanded its presence in London, under the Marylebone Diagnostic Centre brand where it provides a comprehensive range of screening and diagnostic testing services.
  • Marylebone Laboratory brings extensive expertise in NGS (Next-Generation Sequencing) and PCR (Polymerase Chain Reaction)-based molecular genetic testing.

Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom

Retrieved on: 
Tuesday, August 1, 2023

Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics.

Key Points: 
  • Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics.
  • Colorectal cancer remains a critical health concern, with approximately 43,000 diagnoses and 16,800 deaths occurring each year in the UK alone.
  • Mainz Biomed is delighted to collaborate with Marylebone Laboratory, which recently expanded its presence in London under the Marylebone Diagnostic Centre brand, where it provides a comprehensive range of screening and diagnostic testing services.
  • Marylebone Laboratory brings extensive expertise in NGS (Next-Generation Sequencing) and PCR (Polymerase Chain Reaction)-based molecular genetic testing.

Herbalife Science Experts Invited to Present Research at Several Scientific and Regulatory Conferences in the Third Quarter

Retrieved on: 
Wednesday, June 21, 2023

Herbalife, a premier health and wellness company, announced today that members of its scientific and regulatory teams from around the world have been invited to present their scientific research at several conferences in the third quarter of 2023.

Key Points: 
  • Herbalife, a premier health and wellness company, announced today that members of its scientific and regulatory teams from around the world have been invited to present their scientific research at several conferences in the third quarter of 2023.
  • Attendees receive comprehensive education in exercise programming, research, and best business practices.
  • Additionally, Herbalife will award $4,750 USD for best oral and poster presentations to winners selected by a panel of ICANS scientific members.
  • Zhengfei Lu, Ph.D., principal scientist of Molecular Applications at Herbalife, will give a presentation titled, “Application of a Modified Tetra-primer ARMS-PCR Assay for the Authentication of Botanical Identity.”

Global Forensic Technologies Market Report 2023: Sector is Expected to Reach $41.92 Billion by 2030 at a CAGR of 12.28% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 20, 2023

The global forensic technologies market is witnessing significant growth due to advancements in technology and increasing demand for accurate crime investigation tools.

Key Points: 
  • The global forensic technologies market is witnessing significant growth due to advancements in technology and increasing demand for accurate crime investigation tools.
  • The market is expected to continue its upward trajectory, driven by the rising need for effective forensic solutions worldwide.
  • The Global Forensic Technologies market is segmented based on Product, Application, Service, Location, Techniques, and Region.
  • The global market for forensic technologies is witnessing a significant emphasis on two areas: portable forensics and laboratory forensics.

PiQuant Wins CES 2023 Innovation Award for Spectroscopy-based Detection Tool

Retrieved on: 
Monday, February 27, 2023

Co., Ltd. (CEO: Doyeon Pi), a spectroscopy-based environmental IoT company, has won the CES 2023 Innovation Award from the Consumer Technology Association (CTA) of America.

Key Points: 
  • Co., Ltd. (CEO: Doyeon Pi), a spectroscopy-based environmental IoT company, has won the CES 2023 Innovation Award from the Consumer Technology Association (CTA) of America.
  • At this year's event, PiQuant's water quality analyzer "Water Scanner" won the award as the first portable spectrometer to do real-time analysis of the water components.
  • Using PiQuant's portable bacteria water scanner, the detection of E. Coli bacteria can be done within 3 minutes.
  • PiQuant is introducing its products to several developing countries suffering from water pollution, including India and Vietnam.

Body Fluid Collection and Diagnostic Market Report 2022: Surging Demand for Fluid Analysis Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 24, 2023

The body fluid collection and diagnostic market size is estimated to be USD 30,525.12 million in 2022 and is expected to witness a CAGR of 7.87% during the forecast period 2023-2033.

Key Points: 
  • The body fluid collection and diagnostic market size is estimated to be USD 30,525.12 million in 2022 and is expected to witness a CAGR of 7.87% during the forecast period 2023-2033.
  • It is anticipated that the rising demand for Direct-to-Consumer testing (DTC) will increase demand for body fluid collection and make it simpler for end users to gather samples.
  • A number of players directly sell DTC sample collection kits to consumers and then analyse the samples they collect.
  • Body fluid testing has benefits for disease diagnosis and monitoring, including low cost, low invasiveness, and speedy sample collection and processing.

Body Fluid Collection and Diagnostic Market Report 2022: Sector to Expand by 7.87% Annually Through 2033

Retrieved on: 
Wednesday, January 25, 2023

The body fluid collection and diagnostic market size is estimated to be USD 30,525.12 million in 2022 and is expected to witness a CAGR of 7.87% during the forecast period 2023-2033.

Key Points: 
  • The body fluid collection and diagnostic market size is estimated to be USD 30,525.12 million in 2022 and is expected to witness a CAGR of 7.87% during the forecast period 2023-2033.
  • A number of players directly sell DTC sample collection kits to consumers and then analyse the samples they collect.
  • Body fluid remains found at crime scenes are critical pieces of evidence for forensic investigators.
  • Body fluid testing has benefits for disease diagnosis and monitoring, including low cost, low invasiveness, and speedy sample collection and processing.

BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.

Retrieved on: 
Sunday, January 22, 2023

BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.

Key Points: 
  • BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.
  • Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.
    BIOSYNEX (ISIN : FR0011005933, Mnémonique :ALBIO), a major player in public health, announces the extension of its partnership with the Singaporean company Credo Diagnostics Biomedical Pte Ltd (“Credo Diagnostics”).
  • BIOSYNEX and Credo Diagnostics have recently strengthened their collaboration by signing an exclusivity agreement for an extended territory including the United Kingdom.
  • Larry Abensur, Chaiman and CEO of BIOSYNEX: “Our collaboration with Credo Diagnostics has greatly contributed to making BIOSYNEX a key player in Covid-19 diagnostics in France.